Instil Bio Inc (TIL)
Instil Bio, Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ under the ticker TIL. The company is developing a pipeline of experimental therapies, with AXN-2510/IMM2510 as its lead candidate. That program is being studied in a Phase 1b/2 trial in patients with advanced or metastatic non-small cell lung cancer who have received chemotherapy, and in a separate Phase 1 open-label study in China evaluating the therapy as a single agent in advanced solid tumors. The broader trial program includes tumor types such as triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, soft tissue sarcomas, and thymic cancer. Instil Bio was incorporated in 2018 and is headquartered in Dallas, Texas.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TIL
|
$9.74
|
31.6% Upside
|
Undervalued
|
$7
|
-5.4% Downside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-1.1x
|
0.5x
|
—
|
49.169 M
|
60.462 M
|
63.4%
|
53.4%
|
-4.4
|
—
|
71.3%
|
